Standard BioTools Q2 2026 Earnings: Cost Cuts Narrow the Adjusted EBITDA Loss

Standard BioTools (NASDAQ: LAB) reported Q2 2026 revenue of $20.1 million, down 7.6% year over year, while diluted loss per share from continuing operations widened to $0.06 from $0.05. Cost reductions and higher gross margin narrowed the adjusted EBITDA loss substantially, but transaction expenses caused the GAAP net loss from continuing operations to increase.

Core Performance Data

Revenue declined across consumables, instruments, and services. Nevertheless, productivity improvements and lower warranty expense lifted GAAP gross margin by 3.6 percentage points, allowing gross profit to remain nearly unchanged despite the lower sales base.

The earnings picture differed sharply between GAAP and adjusted results. Non-GAAP operating expenses fell 50% following restructuring actions, but $14.7 million of transaction and integration expenses kept total GAAP operating expenses close to the prior-year level.

Business and Revenue Performance

Consumables remained Standard BioTools’ largest revenue category but recorded the steepest dollar decline. The company attributed the decrease to a particularly strong prior-year comparison and continued uncertainty in U.S. academic spending. Instrument demand remained affected by capital constraints in end markets, while services revenue also declined.

The results show that the revenue contraction was not confined to one product line. Consumables faced academic funding uncertainty, while instruments remained sensitive to customers’ capital budgets.

Profitability, Cash Flow and Balance Sheet

GAAP gross profit was $10.5 million, nearly unchanged from $10.6 million a year earlier, because the improvement in gross margin offset most of the revenue decline. Non-GAAP gross margin also increased, reaching 56.3% from 54.1%.

Standard BioTools ended June with $541.1 million in cash, cash equivalents, restricted cash, and short- and long-term investments, compared with $227.9 million one year earlier. Cash and cash equivalents alone totaled $270.0 million, with another $274.0 million held in short- and long-term investments.

Cash generation from operations remained negative. For the first six months of 2026—not the second quarter alone—net cash used in operating activities was $56.9 million, compared with $51.0 million in the prior-year period. These cash-flow figures include continuing and discontinued operations. Investing activities provided $205.5 million, primarily reflecting $388.2 million of net cash received from the sale of a business.

Merger Costs Obscured Operating Savings as the Company Withdrew Its Outlook

The central earnings divergence came from the gap between reported and adjusted expenses. Research and development expense fell to $2.0 million from $6.2 million, while selling, general and administrative expense declined to $16.4 million from $28.1 million. Those reductions helped cut non-GAAP operating expenses in half and narrowed the adjusted EBITDA loss by $13.6 million.

However, transaction and integration expenses rose to $14.7 million from $0.3 million, and the company recorded another $2.8 million of restructuring charges. As a result, GAAP operating expenses declined only 1%, while the continuing-operations net loss widened despite the improvement in adjusted EBITDA.

The transaction process is also affecting forward visibility. Standard BioTools withdrew its full-year 2026 revenue outlook because of the pending merger with Treeline Biosciences. Management said the merger is progressing toward a stockholder vote and is anticipated to close before the end of 2026, subject to approval and other closing conditions.

Risks Investors Need to Watch

• Continued pressure on research spending: Uncertainty in U.S. academic budgets contributed to the consumables decline and could continue to weigh on the company’s largest revenue category.
• Capital constraints among instrument customers: Instrument revenue remained under pressure from capital-constrained end markets, limiting recovery in equipment sales.
• Merger and divestiture execution: The Treeline merger requires stockholder approval and other closing conditions. Delays or failure to complete the merger or the proposed Mass Cytometry divestiture could increase costs and disrupt operations.
• Ongoing cash use: Despite substantial liquidity, operating cash outflow for the first half increased from the prior-year period. Investors will need to distinguish proceeds from asset sales from cash generated by the underlying business.
• Reduced outlook visibility: Withdrawal of the full-year revenue outlook removes a quantitative benchmark for evaluating performance during the remainder of 2026.

Summary

Standard BioTools’ second quarter combined weaker revenue with a materially leaner underlying cost structure. All three revenue categories declined, but higher gross margin and restructuring-led expense reductions sharply improved adjusted EBITDA. Transaction costs prevented those operating savings from reaching the GAAP bottom line, making demand trends, operating cash use, and completion of the Treeline merger the principal issues to monitor.